Organon & Co. (NYSE:OGN) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of Organon & Co. (NYSE:OGN) from a strong sell rating to a hold rating in a report issued on Tuesday morning,Zacks.com reports.

OGN has been the subject of several other reports. Wall Street Zen cut Organon & Co. from a “buy” rating to a “hold” rating in a research note on Saturday, January 31st. Barclays lifted their target price on Organon & Co. from $7.50 to $8.00 and gave the company an “underweight” rating in a research note on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, two have given a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $8.50.

Organon & Co. Trading Up 6.4%

OGN stock opened at $9.26 on Tuesday. The business has a fifty day moving average price of $6.97 and a 200 day moving average price of $7.71. Organon & Co. has a fifty-two week low of $5.69 and a fifty-two week high of $13.24. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of 13.04, a P/E/G ratio of 0.80 and a beta of 0.67. The company has a debt-to-equity ratio of 11.47, a current ratio of 1.82 and a quick ratio of 1.23.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, February 12th. The company reported $0.63 earnings per share for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.10). Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. The business had revenue of $1.51 billion for the quarter, compared to analyst estimates of $1.52 billion. During the same period in the prior year, the business earned $0.90 earnings per share. The company’s revenue for the quarter was down 5.3% on a year-over-year basis. Analysts expect that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 12th. Stockholders of record on Monday, February 23rd were given a $0.02 dividend. This represents a $0.08 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Monday, February 23rd. Organon & Co.’s dividend payout ratio (DPR) is currently 11.27%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Foster Dykema Cabot & Partners LLC bought a new position in shares of Organon & Co. in the 3rd quarter worth $29,000. Rothschild Investment LLC boosted its position in shares of Organon & Co. by 73.1% in the 3rd quarter. Rothschild Investment LLC now owns 3,899 shares of the company’s stock worth $42,000 after purchasing an additional 1,646 shares during the last quarter. Farther Finance Advisors LLC boosted its position in shares of Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock worth $31,000 after purchasing an additional 2,033 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in shares of Organon & Co. by 70.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 5,113 shares of the company’s stock worth $53,000 after purchasing an additional 2,109 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. bought a new position in shares of Organon & Co. in the 4th quarter worth $44,000. 77.43% of the stock is currently owned by institutional investors.

About Organon & Co.

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.